Qx Therapeutics reports that the FDA has cleared the company’s Investigational New Drug application for investigating its lead investigational drug product, QXT-101, for a Phase 2 clinical trial of the safety and efficacy of QXT-101 in hospitalized patients with severe or critical coronavirus disease.
“This is a major milestone not only for the development of QXT-101 as a potential drug product but also for patients with COVID-19 infection,” said Xiaofeng Li, Ph.D., President and CEO of Qx Therapeutics.